GSK2556286
Based on 1 Customer Validation
GSK2556286 (GSK286) is an orally active and cholesterol-dependent Mycobacterium tuberculosis inhibitor. GSK2556286 inhibits Mycobacterium tuberculosis inside infected macrophages (IC50 = 0.07 μM in THP-1 cells), in the presence of cholesterol. GSK2556286 acts via Rv1625c, a membrane-bound adenylyl cyclase in Mycobacterium tuberculosis. GSK2556286 is an Rv1625 agonist leading to increased cAMP and reduced cholesterol metabolism. GSK2556286 can be studied in research for antitubercular purposes.
For research use only. We do not sell to patients.
- Purity: 99.70%
- CAS No.: 1210456-20-4
- Formula: C18H23N3O3
- Molecular Weight:329.39
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Clinical Compound Library
HY-L026
-
Antibacterial Compound Library
HY-L049
-
Orally Active Compound Library
HY-L061
-
Heterocyclic Compound Library
HY-L138
-
Anti-tuberculosis Compound Library
HY-L142
-
Macrophage Related Compound Library
HY-L174
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
IC50: 0.07 μM (human macrophage)[1]
GSK2556286 requires the presence of cholesterol to demonstrate activity in axenic culture with IC50 of 2.12 and 0.71 μM in H37Rv and Erdman respectively, whilst the IC50 with glucose medium is >125 and >50 μM in H37Rv and Erdman respectively[2].
GSK2556286 (5 μM, 24 h) increases the intracellular cAMP levels around 50-fold higher in M. tuberculosis lysates than untreated cells only when Rv1625c is expressed[1].
GSK2556286 (10 μM) reduces the amount of 14CO2 released from 14C-cholesterol by 90% and the propionyl-CoA levels in M. tuberculosis when bacteria cultured in cholesterol media supplemented with acetate[1].
GSK2556286 (1 nM-10 μM) exhibits decreased MIC in cholesterol media around 10-fold and decreased concertration required to inhibit GFP signal in wild-type M. tuberculosis overexpressing rv1625c[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | Vd | T1/2 | Bioavailability | Clearance (CL) |
|---|---|---|---|---|---|---|
| Dog | 3 mg/kg | p.o. | 2.50 L/kg | 1.92 h | 51.3 % | 23.7 mL/min/kg |
| Dog | 5 mg/kg | i.v. | 2.50 L/kg | 1.92 h | 51.3 % | 23.7 mL/min/kg |
| Mice | 1 mg/kg | i.v. | 1.76 L/kg | 2.47 h | 99.0 % | 9.02 mL/min/kg |
| Mice | 10 mg/kg | p.o. | 1.76 L/kg | 2.47 h | 99.0 % | 9.02 mL/min/kg |
| Rat | 5 mg/kg | i.v. | 2.1 L/kg | 2.31 h | 49.8 % | 34.7 mL/min/kg |
| Rat | 5 mg/kg | p.o. | 2.1 L/kg | 2.31 h | 49.8 % | 34.7 mL/min/kg |
GSK2556286 (10-200 mg/kg, p.o., 5 days per week for 4 weeks) shows a significant bactericidal effect in chronic TB infection BALB/c and C3HeB/FeJ mice model, and the maximal effect is achieved with around 10 mg/kg[2].
GSK2556286 (50 mg/kg, p.o., one single dose) has increased efficacy when coadministered with Bedaquiline (B) (HY-14881) (25 mg/kg) and Pretomanid (Pa) (HY-10844) (100 mg/kg) in subacute infection model in BALB/c mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Subacute infection model in BALB/c mice[2]
-
Dosage:50 mg/kg
-
Administration:Oral gavage (p.o.)
-
Result:Resulted in significantly lower lung CFU counts when combined with BPa, BL or BPaL.
Was less active when combined with BL or PaL than BPaL.
Resulted in lower proportions of mice relapsing when combined with BPa or BPaL in comparison with RHZ for 4 months.
Associated with significantly more relapses when combined with PaL, and more relapses after 2 months of treatment when combined with BL.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1210456-20-4
-
Appearance Solid
-
Molecular Weight 329.39
-
Formula C18H23N3O3
-
Color White to off-white
-
SMILES
O=C1C=C(CN2CCC(CC2)OC3=CC=CC(C)=C3C)NC(N1)=O
-
Synonyms
GSK286
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 3.33 mg/mL (10.11 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0359 mL | 15.1796 mL | 30.3591 mL | 75.8979 mL |
| 5 mM | 0.6072 mL | 3.0359 mL | 6.0718 mL | 15.1796 mL | |
| 10 mM | 0.3036 mL | 1.5180 mL | 3.0359 mL | 7.5898 mL |
GSK2556286 Related Classifications
HY-147017 Related Classifications
Powered by Bioz